SAB Biotherapeutics
NASDAQ: SABSMiami Beach, US · Founded 2020 · Delaware corporation
Find your way into SAB Biotherapeutics
337 people in our graph share verified history with the SAB Biotherapeutics team — schools, employers, funds. One of them is your warm intro.
Scott Pulsipherunlockedknows Eddie J Sullivan · together at Brigham Young University (overlapped)
knows the team · via University of Arizona
×2knows the team · via Clark University
×2knows the team · via University of Pennsylvania School of Medicine
knows the team · via University of Rochester - Simon Business School
×3knows the team · via St. Lawrence University
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G antibodies to treat autoimmune and immune disorders, with its lead candidate SAB-142 in development for type 1 diabetes using a proprietary platform that engineers cattle to produce human antibodies without plasma donors.
Founders & leadership
SAB Biotherapeutics was founded in 2020 by Eddie Sullivan and Eddie J Sullivan.
ES
Eddie SullivaninCo-founderEddie Sullivan is an executive officer and director at SAB Biotherapeutics with background in biotechnology, vaccine development, and infectious disease expertise.
EJ
Eddie J SullivaninFounderFounder and chief executive of SAB Biotherapeutics, a biotechnology company, with experience in areas including FDA regulation, life sciences, vaccines, laboratory work, and infectious diseases. He also has a background in business development and organizational development.
SR
Samuel ReichinExecutiveSamuel Reich holds a B.A. in Biochemistry from Clark University and pursued doctoral research in Jean Bennett's lab at the University of Pennsylvania before founding Acuity Pharmaceuticals in 2002 and Biscayne Neurotherapeutics in 2011, both of which were acquired by larger pharmaceutical firms; he joined SAB Biotherapeutics as Executive Chairman in 2021 following the company's merger with Big Cypress Acquisition Group, where he had served as Chief Executive Officer and Chief Financial Officer.
RB
Russell BeyerinExecutiveRussell Beyer is an Executive Officer at SAB Biotherapeutics who previously held senior finance and operations roles at Fortune 100 pharmaceutical and technology companies including AstraZeneca, Teva Pharmaceuticals, World Fuel Services, and Hewlett Packard, with experience in business transformation, merger integration, and international operations across Europe, Latin America, and the United States.
SJ
Samuel J. ReichinClass III Director, Chief Executive OfficerSamuel J. Reich is Chief Executive Officer of SAB Biotherapeutics, which he joined in 2021 following its combination with Big Cypress Acquisition Group, where he served as Chief Executive Officer and Chief Financial Officer. He previously co-founded Biscayne Neurotherapeutics in 2011 (sold to Supernus Pharmaceuticals in 2018) and founded Acuity Pharmaceuticals in 2002 (acquired by Opko Health). Reich holds a B.A. in Biochemistry from Clark University and a M.S. from the University of Pennsylvania, where he conducted doctoral research on gene therapy applications, and is an inventor on multiple U.S. and international patents related to RNA interference therapeutics.
Board
JS
Jeffrey SpragensBoard director
AM
Andrew MoinBoard director
JS
Jay SkylerBoard director
EL
Erick LuceraBoard director
WP
William PolvinoBoard director
KE
Katie ElliasBoard director
DL
David LinkBoard director
Reported raises · per SEC filings
Form D private placements$182.5M disclosed across 2 rounds · 2023–2025
▶$175MraisedAug 2025 · 17 investors · BiotechnologyRule 506(b)
▶$175MraisedAug 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MoinDirector
- Jay SkylerDirector
- Erick LuceraDirector
- Samuel ReichExecutive Officer, Director
- William PolvinoDirector
- Katie ElliasDirector
- Eddie SullivanExecutive Officer, Director
- Jeffrey SpragensDirector
- David LinkDirector
- Scott GibersonDirector
- Christine HamiltonDirector
- Offering amount
- $175M
- Amount sold
- $175M
- Sales commissions
- $10.5M
- Placement agents
- Oppenheimer & Co. Inc., Chardan Capital Markets, LLC, Leerink Partners LLC, UBS SECURITIES LLC
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$7.5MraisedOct 2023 · 13 investors · BiotechnologyRule 506(b)
▶$7.5MraisedOct 2023 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Russell BeyerExecutive Officer
- Erick LuceraDirector
- David Charles LinkDirector
- Samuel ReichExecutive Officer, Director
- Eddie J. SullivanExecutive Officer, Director
- William PolvinoDirector
- Christine HamiltonDirector
- Scott GibersonDirector
- Andrew MoinDirector
- Jeffrey G. SpragensDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- Sales commissions
- $450K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $199.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.4M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does SAB Biotherapeutics do?
- SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G antibodies to treat autoimmune and immune disorders, with its lead candidate SAB-142 in development for type 1 diabetes using a proprietary platform that engineers cattle to produce human antibodies without plasma donors.
- Who founded SAB Biotherapeutics?
- SAB Biotherapeutics was founded by Eddie Sullivan, Eddie J Sullivan in 2020.
- How much funding has SAB Biotherapeutics raised?
- SAB Biotherapeutics has disclosed $182.5M raised across 2 rounds.
- Where is SAB Biotherapeutics headquartered?
- SAB Biotherapeutics is headquartered in Miami Beach, US.